Company intelligence / Profile preview

Alltrna

Cambridge, Massachusetts, United Statesalltrna.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Alltrna has presented robust preclinical proof-of-concept data showing clinically relevant protein restoration in two disease models representing different metabolic disorders caused by premature stop codons. The company’s lead program, AP003, demonstrated activity supporting a basket approach for treating multiple rare genetic liver diseases with shared PTCs. IND-enabling studies are underway.

Therapeutic areas: Rare Diseases
Modalities: tRNA therapeutics (engineered transfer RNA medicines)
Industry: Biotech

Drug pipeline

2 assets

AP003

1 more asset in the full pipeline.

Partnerships

No major external pharma partnerships disclosed; closely tied to Flagship Pioneering ecosystem.

Beyond the preview

Go deeper on Alltrna.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alltrna.